Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

1. Gianni, L.
2. Huang, C.S.
3. Egle, D.
4. Bermejo, B.
5. Zamagni, C.
6. Thill, M.
7. Anton, A.
8. Zambelli, S.
9. Bianchini, G.
10. Russo, S.
11. Ciruelos, E.M.
12. Greil, R.
13. Semiglazov, V.
14. Colleoni, M.
15. Kelly, C.
16. Mariani, G.
17. Del Mastro, L.
18. Maffeis, I.
19. Valagussa, P.
20. Viale, G.